BioPharma Resources

Drug Trial Radar · NCT07221227

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Title says "pivotal". Randomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Oct 24, 2025

Primary completion

Mar 29, 2028

Study completion Dec 12, 2031

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.

Conditions

  • Non-alcoholic Fatty Liver Disease

Interventions

  • Efimosfermin alfaDrug

    Efimosfermin alfa will be administered

  • Efimosfermin alfaDrug

    Efimosfermin alfa will be administered

  • PlaceboDrug

    Placebo will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants experiencing improvement in fibrosis by >=1 stage and no worsening of steatohepatitis at Week 52Time frame: At Week 52
  2. Proportion of participants experiencing resolution of steatohepatitis reading and no worsening of MASH CRN fibrosis score at Week 52Time frame: At Week 52
  3. Time from randomization to an adjudicated composite liver-related clinical outcomeTime frame: From Randomization (Day 1) to 48 months

Locations

91 sites in 9 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Chandler, Arizona · Recruiting

  • GSK Investigational Site

    Tucson, Arizona · Recruiting

  • GSK Investigational Site

    Little Rock, Arkansas · Recruiting

  • GSK Investigational Site

    Arcadia, California · Recruiting

  • GSK Investigational Site

    Covina, California · Recruiting

  • GSK Investigational Site

    Folsom, California · Recruiting

  • GSK Investigational Site

    Los Angeles, California · Recruiting

  • GSK Investigational Site

    Montclair, California · Recruiting

  • GSK Investigational Site

    Riverdale, California · Recruiting

  • GSK Investigational Site

    San Diego, California · Recruiting

  • GSK Investigational Site

    Santa Maria, California · Recruiting

  • GSK Investigational Site

    Van Nuys, California · Recruiting

  • GSK Investigational Site

    Colorado Springs, Colorado · Recruiting

  • GSK Investigational Site

    Boynton Beach, Florida · Recruiting

  • GSK Investigational Site

    Cape Coral, Florida · Recruiting

  • GSK Investigational Site

    Clermont, Florida · Recruiting

  • GSK Investigational Site

    Fort Myers, Florida · Recruiting

  • GSK Investigational Site

    Hialeah, Florida · Recruiting

  • GSK Investigational Site

    Hialeah, Florida · Recruiting

  • GSK Investigational Site

    Homestead, Florida · Recruiting

  • GSK Investigational Site

    Inverness, Florida · Recruiting

  • GSK Investigational Site

    Jacksonville, Florida · Recruiting

  • GSK Investigational Site

    Kissimmee, Florida · Recruiting

  • GSK Investigational Site

    Lakeland, Florida · Recruiting

  • GSK Investigational Site

    Maitland, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami Lakes, Florida · Recruiting

  • GSK Investigational Site

    Ocala, Florida · Recruiting

  • GSK Investigational Site

    Palmetto Bay, Florida · Recruiting

  • GSK Investigational Site

    Sarasota, Florida · Recruiting

  • GSK Investigational Site

    Marietta, Georgia · Recruiting

  • GSK Investigational Site

    Topeka, Kansas · Recruiting

  • GSK Investigational Site

    Bastrop, Louisiana · Recruiting

  • GSK Investigational Site

    Marrero, Louisiana · Recruiting

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.